Consistent with increased obesity, insulin resistance and FFAs HFD-fed mice treated with CPF and housed at TN had increased liver weights (Fig. 2i), liver TGs (Fig. 2j, k) and serum ALT (Fig. 2l) and AST (Fig. 2m) indicative of greater NAFLD than HFD controls. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.